Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00099502
Status:
COMPLETED
Last Update Posted:
2008-12-19
First Post:
2004-12-15
Brief Title:
BEYOND BetaferonBetaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis MS Patients
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
International Randomized Multicenter Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks 1 Double-Blinded Safety Tolerability and Efficacy of Betaseron Betaferon 250 µg 8 MIU and Betaseron-Betaferon 500 µg 16 MIU Both Given Subcutaneously Every Other Day and 2 Rater-Blinded Safety Tolerability and Efficacy of Betaseron-Betaferon sc Every Other Day With Copaxone 20 mg sc Once Daily
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine
whether treatment with Betaferon Betaseron interferon beta-1b 500 micrograms safe tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms
whether treatment with Betaferon Betaseron interferon beta-1b tolerable and more efficacious than treatment with Copaxone Glatiramer Acetate 20 mg
whether treatment with Betaferon Betaseron interferon beta-1b 500 micrograms safe tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms
whether treatment with Betaferon Betaseron interferon beta-1b tolerable and more efficacious than treatment with Copaxone Glatiramer Acetate 20 mg
Detailed Description:
This study has previously been posted by Berlex Inc and Schering AG Germany Berlex Inc has been renamed to Bayer HealthCare Pharmaceuticals Inc Schering AG Germany has been renamed to Bayer Schering Pharma AG Germany
Bayer HealthCare Pharmaceuticals Incand Bayer Schering Pharma AG Germany are the sponsors of the trial
Bayer HealthCare Pharmaceuticals Incand Bayer Schering Pharma AG Germany are the sponsors of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT 2005-002235-27 | None | None | None |
| 306440 | None | None | None |
| Beyond | None | None | None |